TaiMed Biologics 将来の成長

Future 基準チェック /06

TaiMed Biologicsの収益は年間0.07%で減少すると予測されていますが、年間収益は年間5.4%で増加すると予想されています。EPS は年間0.2%で減少すると予想されています。

主要情報

-0.07%

収益成長率

-0.2%

EPS成長率

Biotechs 収益成長	51.2%
収益成長率	5.4%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	30 Oct 2024

今後の成長に関する最新情報

Recent updates

TaiMed Biologics Inc.'s (GTSM:4147) Profit Outlook

Apr 20

TaiMed Biologics Inc. (GTSM:4147) Analysts Just Trimmed Their Revenue Forecasts By 18%

Mar 16

業績と収益の成長予測

TPEX:4147 - アナリストの将来予測と過去の財務データ ( )TWD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2025	660	-141	-58	-319	3
12/31/2024	615	-138	7	-45	3
9/30/2024	623	-142	136	157	N/A
6/30/2024	642	-110	107	120	N/A
3/31/2024	599	-130	80	86	N/A
12/31/2023	492	-195	-32	-26	N/A
9/30/2023	660	-172	-61	-56	N/A
6/30/2023	599	-202	-104	-99	N/A
3/31/2023	594	-230	-562	-558	N/A
12/31/2022	563	-269	-610	-605	N/A
9/30/2022	312	-530	-531	-524	N/A
6/30/2022	307	-572	-515	-505	N/A
3/31/2022	363	-596	-92	-81	N/A
12/31/2021	413	-471	-225	-211	N/A
9/30/2021	490	-264	-437	-231	N/A
6/30/2021	551	-233	-471	-222	N/A
3/31/2021	575	-103	-812	-446	N/A
12/31/2020	722	-183	-588	-202	N/A
9/30/2020	779	-173	-795	-618	N/A
6/30/2020	839	-450	-1,023	-815	N/A
3/31/2020	815	-564	-701	-580	N/A
12/31/2019	705	-579	-793	-655	N/A
9/30/2019	611	-650	-823	-459	N/A
6/30/2019	486	-684	-840	-489	N/A
3/31/2019	369	-539	-1,696	-498	N/A
12/31/2018	241	-322	-1,708	-523	N/A
9/30/2018	128	-335	-1,721	-530	N/A
6/30/2018	43	-83	N/A	-523	N/A
3/31/2018	7	-316	N/A	-552	N/A
12/31/2017	8	-525	N/A	-516	N/A
9/30/2017	7	-466	N/A	-403	N/A
6/30/2017	5	-410	N/A	-223	N/A
3/31/2017	3	-307	N/A	-241	N/A
12/31/2016	2	-282	N/A	-172	N/A
9/30/2016	1	-285	N/A	-316	N/A
6/30/2016	1	-423	N/A	-392	N/A
3/31/2016	0	-465	N/A	-384	N/A
12/31/2015	N/A	-472	N/A	-446	N/A
9/30/2015	N/A	-441	N/A	-312	N/A
6/30/2015	N/A	-333	N/A	-230	N/A
3/31/2015	N/A	-273	N/A	-209	N/A
12/31/2014	N/A	-282	N/A	-213	N/A
9/30/2014	N/A	-285	N/A	-200	N/A
6/30/2014	N/A	-289	N/A	-215	N/A
3/31/2014	N/A	-280	N/A	-213	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 4147今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: 4147今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: 4147今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: 4147の収益 ( 5.4% ) TW市場 ( 12.5% ) よりも低い成長が予測されています。

高い収益成長: 4147の収益 ( 5.4% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 4147の自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

TaiMed Biologics 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

No longer forecast to breakeven

Price target increased by 17% to NT$152

Forecast breakeven date moved forward to 2024

Forecast breakeven date moved forward to 2024

Consensus revenue estimates decrease by 25%

No longer forecast to breakeven

Recent updates

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Taimed Biologics Inc. Receives Patent Approval from China for Improving the Pharmacokinetic Performance of Tmb-365 Using Histidine Modification Technology

No longer forecast to breakeven

Price target increased by 17% to NT$152

Second quarter 2024 earnings: Revenues exceed analyst expectations

TaiMed Biologics Inc. to Report Q2, 2024 Results on Aug 08, 2024

TaiMed Biologics Inc. Receives Patent Approval from the US PTO for Improving the Pharmacokinetic Performance of TMB-365 Using Histidine Modification Technology

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

TaiMed Biologics Inc. Announces Enrollment of the Last Patient in Phase 2a Study of the Long-Acting TMB-365/TMB-380 Mabcombination for the Bi-Monthly Maintenance HIV Therapy

TaiMed Biologics Inc. to Report Q1, 2024 Results on May 13, 2024

New minor risk - Shareholder dilution

Forecast breakeven date moved forward to 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

TaiMed Biologics Inc., Annual General Meeting, May 28, 2024

Forecast breakeven date moved forward to 2024

Consensus revenue estimates decrease by 25%

No longer forecast to breakeven

TaiMed Biologics Inc. Receives Patent Approval from the Taiwan Intellectual Property Office for Improving the Pharmacokinetic Performance of TMB-365 Using Histidine Modification Technology

TaiMed Biologics Inc. Revises the Phase 2 Clinical Study Design of Bi-Monthly Dosing of TMB-365/TMB-380 Combination for the Treatment of HIV Infection

Taimed Biologics Inc. Announces US FAD Approves the sBLA for the IV Push Administration of the Loading Dose of Trogarzo

TaiMed Biologics Inc. has filed a Follow-on Equity Offering.

TaiMed Biologics Inc. has filed a Follow-on Equity Offering.

TaiMed Biologics Inc. Announces Results from Trogarzo Intramuscular (IM) Administration Study

No longer forecast to breakeven

No longer forecast to breakeven

New minor risk - Profitability

TaiMed Biologics Inc. Completes Data Analysis of the Clinical Trial Sentinel Group for the TMB-365 and TMB-380 Combination as Expected and Confirms the Dosing for Future Execution

Forecast to breakeven in 2024

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

TaiMed Biologics Inc. Completes the Last Patient Visit of the Sentinel Group in the Clinical Study Evaluating Long-Acting TMB-365/TMB-380 Combination Maintenance Therapy

Consensus revenue estimates decrease by 56%, EPS upgraded

Consensus revenue estimates decrease by 29%, EPS upgraded

Price target increased by 31% to NT$133

Forecast to breakeven in 2024

Less than half of directors are independent

Consensus forecasts updated

Second quarter 2022 earnings: EPS in line with expectations, revenues disappoint

TaiMed Biologics Inc. Announces First Patient Enrolled in the Study Evaluating Bi-monthly and Quarterly Dosing of the Long-Acting TMB-365/TMB-380 mAb Combination Maintenance Therapy

TaiMed Biologics Inc. Approves Board Appointments

TaiMed Biologics Inc. Receives Official Approval Letter from US FDA

First quarter 2022 earnings: EPS exceeds analyst expectations

Consensus revenue estimates fall by 48%

Forecast breakeven date pushed back to 2023

TaiMed Biologics Inc. Announces Enrollment of Phase III Clinical Study is Complete for Trogarzo Intramuscular Injection (IM)

Price target increased to NT$109

Less than half of directors are independent

Forecast breakeven date pushed back to 2023

TaiMed Biologics Inc. Announces Change of CEO

Taimed Biologics Inc. Announces FDA Approves 1b/2a Clinical Studying Two Monoclonal Antibody

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased to NT$109

TaiMed Biologics Inc. Submits Initial Safety and Efficacy Results of the Phase I Clinical Trial of Tmb-365 to the US Food and Drug Administration

TaiMed Biologics Inc. Announces US FDA Approves Supplemental BLA Filing for the Addition of Samsung Biologics in Korea for Commercial Manufacturing of Trogarzo

Taimed Biologics Inc. Announces the Presentation of Positive Results from Trogarzo IV Push Administration Study

Forecast breakeven date pushed back to 2023

Third quarter 2021 earnings released: NT$0.31 loss per share (vs NT$0.18 loss in 3Q 2020)

Second quarter 2021 earnings released: NT$0.39 loss per share (vs NT$0.12 profit in 2Q 2020)

First quarter 2021 earnings released: EPS NT$0.02 (vs NT$0.30 loss in 1Q 2020)

TaiMed Biologics Inc.'s (GTSM:4147) Profit Outlook

Full year 2020 earnings released: NT$0.73 loss per share (vs NT$2.30 loss in FY 2019)

TaiMed Biologics Inc. (GTSM:4147) Analysts Just Trimmed Their Revenue Forecasts By 18%

TaiMed Biologics Inc., Annual General Meeting, May 31, 2021

TaiMed Biologics'(GTSM:4147) Share Price Is Down 67% Over The Past Five Years.

New 90-day low: NT$78.60

Loss-Making TaiMed Biologics Inc. (GTSM:4147) Set To Breakeven

New 90-day low: NT$85.90

TaiMed Biologics (GTSM:4147) Has Debt But No Earnings; Should You Worry?

Revenue and earnings miss expectations

Third quarter 2020 earnings released: NT$0.18 loss per share